Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Brawn BiotechBOM:530207 +4.99%55 Return-on-Tangible-Equity is 53.78% as of Mar. 2026, which is 21412% above its 10-year median of 0.25. GuruFocus rates BOM:530207 with a GF Score™ of 55/100 and a GF Value™ of ₹20.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 896 Drug Manufacturers companies, Brawn Biotech ranks better than 83.15% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Brawn Biotech's annualized net income for the quarter that ended in Mar. 2026 was ₹23.3 Mil. Brawn Biotech's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹43.4 Mil. Therefore, Brawn Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 53.78%.
The historical rank and industry rank for Brawn Biotech's Return-on-Tangible-Equity or its related term are showing as below:
BOM:530207'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -42.67 Med: 0.25 Max: 24.74
Current: 24.74
During the past 13 years, Brawn Biotech's highest Return-on-Tangible-Equity was 24.74%. The lowest was -42.67%. And the median was 0.25%.
BOM:530207's Return-on-Tangible-Equity is ranked better than 83.15% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.645
vs BOM:530207: 24.74
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Brawn Biotech Return-on-Tangible-Equity Related Terms
Brawn Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Brawn Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530207 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brawn Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brawn Biotech Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brawn Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Brawn Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 53.78% mean?
Brawn Biotech (BOM:530207) has a Return-on-Tangible-Equity of 53.78% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Brawn Biotech and its competitors. This is 21412% above median its historical median of 0.25. According to the industry distribution chart, Brawn Biotech ranks #151 out of 896 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is Brawn Biotech's Return-on-Tangible-Equity too high?
Brawn Biotech's current Return-on-Tangible-Equity of 53.78% is 21412% above median its 10-year median of 0.25. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.65. Brawn Biotech's value of 53.78% is 603.5% above this industry median. Based on the distribution chart, Brawn Biotech ranks #151 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Brawn Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brawn Biotech's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Brawn Biotech ranks #151 out of 896 companies for Return-on-Tangible-Equity. This places Brawn Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.65. Brawn Biotech's value of 53.78% is 603.5% above this benchmark. While the company's 10-year median is 0.25 vs. the industry median of 7.65, Brawn Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.65, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brawn Biotech's current Return-on-Tangible-Equity of 53.78% is 603.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Brawn Biotech and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brawn Biotech's current Return-on-Tangible-Equity is 53.78%, which is 21412% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brawn Biotech stock overvalued right now?
Based on GuruFocus' analysis, Brawn Biotech (BOM:530207) is currently considered Fairly Valued. The stock's GF Value™ is ₹20.49, compared to a current price of ₹20.21 — trading 1.4% below its estimated fair value. The current Return-on-Tangible-Equity is 53.78%, which is 21412% above median its 10-year median of 0.25 and 603.5% above the Drug Manufacturers industry median of 7.65. Brawn Biotech's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Brawn Biotech (BOM:530207), the current Return-on-Tangible-Equity is 53.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brawn Biotech (BOM:530207) Overvalued in 2026?
Based on GuruFocus' analysis, Brawn Biotech stock appears to be undervalued.
The current stock price of ₹20.21 is trading 1.4% below its estimated GF Value™ of ₹20.49.
GuruFocus considers Brawn Biotech to be Fairly Valued.
Key valuation signals for BOM:530207:
Return-on-Tangible-Equity: 53.78% (21412% above median its 10-year median of 0.25)
GF Value™: ₹20.49 vs. price of ₹20.21 (1.4% below fair value)
Industry Position: 603.5% above the Drug Manufacturers median (#151 of 896)
No single metric tells the full story. See the BOM:530207 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brawn Biotech Ltd is a healthcare company. It is engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals.
55GF Score
Get the complete analysis for BOM:530207
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530207 has been successfully added to your 
